In this report, comissioned by Janssen in October, 2020, we estimate the following mantle cell lymphoma (MCL) patient populations for the years 2020-2030:

  • Diagnosed incident cases
  • Diagnosed prevalent cases
  • Diagnosed incident cases, stratified by drug-treatment status.

Estimates are provided for the following countries:

1. Argentina

2. Brazil

3. Colombia

4. Mexico

5. Panama

6. Guatemala

7. Dominican Republic

8. Costa Rica.

Estimation and forecasting methods and key data sources were adopted in collaboration with national and regional Janssen stakeholders. For more details on the project, please contact or your account manager.

Table of contents

  • Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content
    • NHL & CLL in LATAM
      • NHL & CLL in LATAM - Project Deliverable
    • MCL in LATAM
      • MCL in LATAM - Project Deliverable
    • CLL - Drug Treated Population in LATAM
      • CLL - Drug Treated Population in LATAM - Project Deliverable

Author(s): Mike Hughes, M.Sc., Ph.D.; Pramilesh Tekchand Suryawanshi

Mike Hughes, M.Sc., Ph.D., is the director of the Epidemiology department at DRG, part of Clarivate. He joined DRG in 2006 and has many years’ experience in the mathematical modeling of healthcare service delivery, cardiovascular and cancer epidemiology, biostatistics, meta-analysis, and systematic reviewing. He has been principal author on many published articles in leading international journals in the areas of risk modeling in intensive care and cardiovascular medicine. He also helped develop national guidelines on behalf of NICE and the American College of Chest Physicians for the treatment of atrial fibrillation, stroke, and hypertension. He is particularly interested in modeling patient flows in cancer and methods for forecasting disease burden in noncommunicable epidemiology. Dr. Hughes received his Ph.D. in risk modeling in intensive care in 2003 from City University, London, and his Ph.D. in statistical causation and foundations of probability theory from the University of Nottingham.

Pramilesh Suryawanshi, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. Before joining DRG, Mr. Suryawanshi worked with Pathfinder International in Lepra, the Netherlands Leprosy Relief Foundation, and the National Health Mission. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai, where he worked on several public health projects, including the assessment of social health insurance schemes. He holds a bachelor’s degree in the Indian system of medicine (Ayurveda) from Rajiv Gandhi University of Health Sciences in Karnataka.

Related Reports

Diabetic Macular Edema / Diabetic Retinopathy - Landscape & Forecast - Disease Landscape & Forecast

Patients with proliferative diabetic retinopathy (PDR) experience retinal damage that can eventually lead to debilitating vision deficits and...

View Details

Chronic Obstructive Pulmonary Disease - Landscape & Forecast - Disease Landscape & Forecast

The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand and is expected to grow from approximately $15...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast

The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Access & Reimbursement - Detailed, Expanded Analysis (US)

Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses, and the treatment landscape is entrenched with targeted age...

View Details